Arca
Skip to content
Tools
Tools

Reperfusion injury

Drug research and approvals for reperfusion injury: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 34 studies of reperfusion injury are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 19 open orphan designations naming it.

  • Recruiting worldwide: 34
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 34 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 11

Phase 2 12 of 16

Phase 1 or earlier 6

How its trials ended

256 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 54 whose ending is known, 26% met their primary endpoint, 33% missed it and 41% stopped early.

  • Completed, result not reported11244%
  • Status unknown5923%
  • Ongoing3112%
  • Missed its primary endpoint187%
  • Stopped: other or unclear166%
  • Met its primary endpoint145%
  • Stopped: lack of efficacy21%
  • Stopped: enrollment or feasibility21%
  • Stopped: safety1<1%
  • Stopped: sponsor or business decision1<1%

FDA orphan designations

Approved first, then open designations, newest first; 15 of 19
Nov 6, 2023AlprostadilPrevention of ischemia/reperfusion injury resulting from solid organ transplantation.Institut Georges LopezDesignated
May 31, 2023N-myristoylated -Glu-Ala-Val-Ser-Leu-Lys-Pro-ThrPrevention of ischemia/reperfusion injury in kidney transplantationYoung Therapeutics, LLCDesignated
Dec 14, 2022Ketamine hydrochloridePrevention of ischemia/reperfusion injury during solid organ transplantation.PharmaTher Inc.Designated
Oct 17, 2022Synthetic polymer PEG conjugated to a phospholipid anchor…Prevention of ischemia reperfusion injury during solid organ transplantationiCoat Medical ABDesignated
Feb 15, 2022BucillaminePrevention of ischemia-reperfusion injury during liver transplantationRevive Therapeutics Inc.Designated
Apr 27, 2021DimethyltryptaminePrevention of ischemia-reperfusion injury in patients undergoing solid organ transplantation.Sairiyo Therapeutics Inc.Designated
Jul 10, 2020MitochondriaPrevention of ischemia-reperfusion injury during solid organ transplantationcellvie Inc.Designated
Nov 5, 2018CannabidiolPrevention of ischemia/reperfusion Injury resulting from solid organ transplantationRevive Therapeutics Ltd.Designated
May 2, 2017Macromolecular conjugate of heparin sodium on a polymer…Prevention of ischemia-reperfusion injury associated with solid organ tranplantationCorline Biomedical ABDesignated
Oct 16, 2014Cardiotrophin-1Prevention of ischemia-reperfusion injury in kidney transplant recipientsDigna Biotech, S.L.Designated
Aug 6, 2013Human HeminPrevention of ischemia reperfusion injury in patients undergoing solid organ transplantationBorders Technology Management LtdDesignated
Dec 12, 2011Humanized IgG4 monoclonal antibodyPrevention of ischemia/reperfusion injury associated with solid organ tranplantationNeuramedy Co., Ltd.Designated
Apr 18, 2011Methyl…Prevention of ischemia reperfusion injury associated wth solid organ transplantationEndotis PharmaDesignated
Jan 29, 201017 amino acid peptidePrevention of ischemia reperfusion injury in the lung during lung tranplantationApeptico Forschung und Entwicklung GmbH (APEPTICO)Designated
Oct 28, 2009DiannexinPrevention of ischemia-reperfusion injury in solid organ transplantsAstellas Pharma Global Development, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.